Gene sequencing giant Berry and Kang want to borrow Tianxing instrument listed
Chengdu Tianxing Instrument Co., Ltd., which has been suspended since its opening on June 15, disclosed the Announcement on the Progress of Major Asset Restructuring on the evening of August 29. In this reorganization, Tianxing Instrument will sell all assets, liabilities, business, personnel, etc. currently owned by it to Tianxing Group or its designated third party, and Tianxing Group or its designated third party will purchase it in cash; Xing Instrument issued shares to all shareholders of Berry and Kang to purchase 100% of its shares in Berry and Kang. Domestic genetic companies have obvious competitive advantages in the middle and lower reaches. There are four companies in the first phalanx of the industry mid-stream: Huada Gene, Berry and Kang, Daan Gene, and Boao Bio. The other well-known companies include Annoyouda, Nuohe Zhiyuan, Fandi Bio, Baimaike and so on. If the disclosure of the announcement goes smoothly, it means that Berry and Kang will use the Tianxing instrument to log into the capital market. The announcement shows: "This asset restructuring constitutes a connected transaction and constitutes a major asset restructuring and backdoor listing." From the data display, Tianxing Instrument is mainly engaged in the design, production, processing and sales of automobile and motorcycle parts. The controlling shareholder is Chengdu Tianxing Instrument (Group) Co., Ltd. In order to ensure the orderly progress of this major asset restructuring, “the company intends to continue to plan major asset restructuring matters and apply for continued suspension of tradingâ€. Gao Yang, Chairman of Beijing Berry and Kang Biotechnology Co., Ltd. Founded in May 2010, Berry and Kang is a research and development biotechnology company dedicated to the application of high-throughput gene sequencing technology to provide "non-invasive" total solutions for clinical medical disease screening and diagnosis. The controlling shareholder and the actual controller are Mr. Gao Yang, a natural person. The reporter learned that Berry and Kang's R&D team was led by Dr. Zhou Xingxing, who was involved in the design and development of high-throughput sequencers. He is a leading expert in research, R&D and bioinformatics in the field of high-throughput sequencing and clinical genetic testing. composition. The company was awarded the Zhongguancun High-tech Enterprise Certification in September 2011 and the National High-tech Enterprise Certification in December 2012. Zhou Daixing is the first person to introduce NIPT (Non-invasive Prenatal Testing) into China. In the beginning of 2010, he cooperated with Xiangya Hospital of Central South University to carry out the first phase clinical trial of non-invasive DNA prenatal testing; In April, the company cooperated with Peking Union Medical College Hospital to carry out the second phase clinical trial of non-invasive DNA prenatal testing. After two years of development, Berry and Kang entered 150 hospitals in more than 30 provinces across the country, and Huada Gene became the largest in the field at that time. Two companies. Up to now, Berry and Kang have covered more than 2,000 hospitals with more than 1,000 employees. Fire Fighting Equipment,Mobile Fire Fighting Equipment,Portable Fire Fighting Equipment,Fire Fighting Equipment And Accessories joho(HK) Technology Co. , Ltd. , https://www.joho-safety.com